CellSource Co

CellSource Co Piotroski F-Score

The Piotroski F-Score of CellSource Co (4880.T) as of Oct 28, 2026 is 6. In the previous year, Piotroski F-Score was 5.00 — a change of 20.00% (higher).

Piotroski F-Score

6

YoY

20.00%

Last updated:

Piotroski F-Score of CellSource Co is 2025 6 . Piotroski F-Score of CellSource Co was 2024 5.00 . It decreases by 20.00% higher compared to the previous year.

The CellSource Co Piotroski F-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Piotroski F-Score
Date
Piotroski F-Score
Jan 1, 2018
6.00 JPY
Jan 1, 2019
3.00 JPY
Jan 1, 2020
6.00 JPY
Jan 1, 2021
8.00 JPY
Jan 1, 2022
7.00 JPY
Jan 1, 2023
3.00 JPY
Jan 1, 2024
5.00 JPY
Jan 1, 2025
6.00 JPY
The CellSource Co Piotroski F-Score history
YEARPiotroski F-ScoreYoY
6+20.00%
5+66.67%
3-57.14%
7-12.50%
8+33.33%
6+100.00%
3-50.00%
6—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Piotroski F-Score of CellSource Co is 6 in 2025.

On Eulerpool you can find the complete historical development of Piotroski F-Score CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Piotroski F-Score rates a company from 0-9 based on profitability, leverage, liquidity, and operating efficiency. Scores of 8-9 indicate strong fundamentals.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — CellSource Co

All Key Metrics — CellSource Co